DENVER, Aug. 04, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) (“Mydecine”), is pleased to announce that its subsidiary, Mindleap Health™ (“Mindleap” or the “Company”) based in Vancouver, British Columbia, is expanding it’s digital therapeutic offerings by adding three additional programs to its platform.
Mindleap™ is working towards contributing to the evolution of mental health and enabling the mass adoption of mental health treatments across the world. In order to expand access to world-class mental health solutions, Mindleap is developing new “30-day transformation” programs that will be offered as in-app purchases on the platform this fall.
The new offerings will include comprehensive addiction, psychedelic integration, and holistic wellness programs designed to empower users to improve their wellbeing. The ability to track progress, encourage consistency through gamification will provide additional value to Mindleap users.
The Addiction Recovery Program will be led by Dr. Rick Barnett, a clinical psychologist and an alcohol and drug counselor in independent practice. Dr. Barnett has worked on the frontlines of addiction treatment for over 20 years with a variety of populations in diverse settings. He is an expert in addictive disorders and treatment, working every day to help clients change and improve their lives. Dr. Barnett has a unique ability to blend multiple approaches in meaningful ways to address and recover from numerous types of addictive behaviors (alcohol, drugs, food, sex, nicotine, gambling).
Equipped with advanced education and training in psychopharmacology, Dr. Barnett has served in numerous leadership roles both locally and nationally related to addiction, mental health, and health care reform. He is also the founder of the Center for Addiction Recognition Treatment Education and Recovery (CARTER, Inc), a 501c3 private non-profit organization dedicated to the art and science of achieving lifelong freedom from addiction. The goal of CARTER, Inc. is to transform addiction into enduring health and well-being, a value which has become the cornerstone to his Mindleap program.
The Psychedelic Integration program will be led by Dr. Danielle Wise who brings over 20 years of experience as a psychotherapist and coach, utilizing myriad techniques with a unique specialization on psychedelic integration. Dr. Wise’s clinical focus is primarily centered on relational trauma, combining depth and somatic psychology, neuroscience, and psychedelic research.
Dr. Wise has completed the Psychedelic Research and Training Institute’s (PRATI) comprehensive Ketamine and Psychedelic Medicine Training, which provides practical tools for eliciting transformational sessions and holistic and integrative tools for mental health support.
An avid decriminalization advocate, she is part of the Denver psilocybin decriminalization initiative and the founder of Women’s Leadership in Psychedelics with the Nowak Society, a non profit that provides education, training, and community building around right relationship with psychedelics and psychopharmaceuticals.
Dr. Wise also serves on the advisory board of Unlimited Sciences a psychedelic research non-profit combining data and lived experiences to serve the community, educate the public, and inform policies. Her 30-day program will offer an embodied integration journey with self care practices and contemplations that will assist users in achieving personal transformation for lifelong wholeness making.
The Holistic Wellness program will be led by Jeremy Hoffman who is an experienced spiritual leader that uses innovative modalities including energy clearing, activations, meditation, breathwork to support his clients in achieving harmony of the mind, body and spirit.
Hoffman is renowned internationally for his holistic wellness coaching, and currently works with C-Suite level executives and business leaders to assist them in achieving spiritual balance and fulfillment in their lives. Cultivating the steps that allow people to operate in life with an upgraded mindset and perspective, Hoffman will be sharing his insights on physical, mental, emotional, and spiritual health in his Mindleap program.
Mindleap’s founder Nikolai Vassev commented: “Our focus is on creating real solutions for the mental health crisis and these new offerings will allow Mindleap to have international reach and affect more lives during these times of crisis. The pandemic has left people depressed, isolated and support is needed now more than ever.”
About Mydecine Innovations Group Inc.
Mydecine Innovations Group™ is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ retail mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences, Mindleap Health, and NeuroPharm focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.
About Mindleap Health Inc.
Mindleap is developing an advanced digital health platform that will provide support for people that are looking to achieve personal transformations and overcome mental health challenges. Mindleap is the only digital health platform that combines telehealth with mood, emotion and habit tracking. This is a paradigm shift to conventional mental health as Mindleap personalized support and users have the tools needed to track their progress and take control of their mental health.
|On behalf of the Board of Directors:||Corp Communication:||Public Relations:|
|Joshua Bartch||Charles Lee||Cynthia Salarizadeh|
|Chief Executive Officer||[email protected]||[email protected]|
|[email protected]||+1 (250) 488-6728|
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, but not limited to completion of planned improvements at both the Canadian and US sites on schedule and on budget, the availability of financing needed to complete the Company’s planned improvements on commercially reasonable terms, planned occupancy by the tenant-growers, commencement of operations, differences in yield on expected harvests, delays in obtaining statutory approval for marijuana production plans, issues that may arise throughout the grow period, outdoor crops affected by weather, the ability to mitigate the risk of loss through appropriate insurance policies, and the risks presented by federal statutes that may contradict local and state legislation respecting legalized marijuana. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.